LIST OF GA²FA 2024 TOPICS 

• Challenges in diagnosing food allergy: role of CRD and Oral Food challenges: implementing the proper algorithm according to the context. 
• Socio-economic burden of food allergy and anaphylaxis across the world: report from the GA²LEN ANACARE Working group. 
• Does Cow’s milk allergy still exist?  Facilitating recognition of symptoms and timely management at the primary care level. 
• FPIES: the multifaceted challenges in diagnosis and treatment.
• Eosinophilic esophagitis: from infants to older patients: how is the approach changing?
• Holistic management of food allergy and anaphylaxis:  are biologics fitting the role? 
• Nutritional issues in food allergy: role of processed foods, ensuring proper replacement and caloric intake, role of formulas for special needs. 
• Preventing food allergy: it is possible! Guidance for implementing recommendations at the primary care level and among patients (GA²LEN ANACARE position paper) 
• Increasing prevalence of food allergy: processed foods, microbiome, 
• The Thresholds issue: how much is safe? How can food companies navigate the landscape for adequately protecting the food allergic consumer? 
• Immunotherapy for food allergy: for IgE and non- IgE food allergy: where are we? 
• Which food for immunotherapy? commercial products vs baked food vs raw food: evaluation of different protocols and outcomes including economic analysis 
• Multifood Immunotherapy: ready for clinical practice? 
• Selecting the right patient and right product for food allergen immunotherapy: evaluating the regulatory issues in developing new products 
• New and old biologics in food allergy and anaphylaxis: outcomes of standing alone treatment and in combination with immunotherapy. 
• Food allergy at the community level: managing anaphylaxis and food allergy at school: GA²LEN ANACARE position paper. 
• The GA²LEN ANACARE White Paper on Anaphylaxis: outlining the needs for a community. 
• NEW Consensus Definition on Anaphylaxis:  how to harmonize the language and implementing the consensus definition across the stakeholders. 
• Phenotypes of anaphylaxis:  drug anaphylaxis v’s hymenoptera v’s food anaphylaxis 
• Defining Severe and Refractory anaphylaxis 
• Managing idiopathic anaphylaxis 
• The self-adrenaline auto-injectors: selecting the right dosage, the right device, and the right patient. 
• Educating on managing anaphylaxis in partnership with patient’s organisations: who should do what? 
• Mastocytosis as risk factor for severe anaphylaxis: when to suspect and how to manage? 
• Regulatory challenges in dealing with food allergy and anaphylaxis in 2024: perspectives from EMA, FDA 
• Integrating a management care pathway for anaphylaxis: reporting from the GA²LEN ANACARE working group 
• Socio-Psychological impact of anaphylaxis among patients, families, and caregivers.